Radiopharmaceuticals Startup Secures $175M Funding
Aktis Oncology, a radiopharmaceuticals startup, raises $175M to advance targeted cancer treatments, focusing on specific tissues.
- Latest
- Trending
Aktis Oncology, a radiopharmaceuticals startup, raises $175M to advance targeted cancer treatments, focusing on specific tissues.
PDS Biotech aligns with FDA for Phase 3 trial, reports Q2 2024 financials with reduced net loss and expenses.
DCTY's acquisition marks a milestone in China's biotech scene, introducing advanced TCR and CAR T-cell therapies domestically.
"Iontronic tech shows promise in slowing malignant brain tumor growth by continuously delivering low-dose drugs, bypassing the blood-brain barrier."
"Day One Biopharmaceuticals enhances pipeline, acquiring global rights to promising PTK7-targeting cancer drug DAY301, begins trial soon."
Phase 1 biotech Boundless Bio raised $100 million at a $396 million market cap. Two IPOs are scheduled for the ...
Diversity in biotechnology and venture capital is crucial for driving innovation and breakthroughs in healthcare, according to Dr. Stanley Lewis. ...
Efforts to diversify biotech venture capital funding could lead to innovation, breakthroughs in healthcare, and improved outcomes for minorities.
Cleveland Clinic and IBM join forces to advance immunotherapy research through AI, unlocking new targets for cancer therapy. #Immunotherapy #AI ...
Johnson & Johnson's $2 billion acquisition of Ambrx Biopharma emphasizes its focus on oncology and targeted cancer treatments. #PharmaNews
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.